This study compares clinically and microscopically the response to two treatments, a steroid in cream and a foam that contains a steroid and a vitamin D analogue in patients with plaque psoriasis.

Recruitment & Eligibility

Status: Authorised-recruitment may be ongoing or finished

Sex: All

Target Recruitment: 36

Inclusion Criteria

Patients who agree to participate in the study and sign the informed consent (IC).
Patients diagnosed clinically and / or histologically from plaque psoriasis.
Men or women = 18 years.
Patients willing to comply with the requirements of the protocol and with the capacity to do so.
Outpatient patients
Patients who are candidates for treatment with any of the study medications.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 36
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Hypersensitivity to any of the active principles or any of the excipients that appear listed in the technical data sheet of the study drugs.
Erythrodermic, exfoliative or pustular psoriasis.
Patients with known disorders in calcium metabolism.
Acute renal failure.
Acute liver disorders.
Facial or genital psoriasis.
Patients with viral skin lesions, fungal or bacterial skin infections, parasitic infections, skin manifestations in relation to tuberculosis, perioral dermatitis, atrophic skin, atrophic streaks, fragility of skin veins, ichthyosis, acne vulgaris, acne Rosacea, rosacea, ulcers and wounds.
Systemic treatment including cyclosporin A, methotrexate and steroids in the last 4 weeks.
Patients who have received systemic treatment with biological therapies, commercialized or not, with possible effect on plaque psoriasis during the following periods:
- etanercept: 4 weeks before visit 1 (week 0)
- adalimumab, alefacept, infliximab: 2 months before visit 1 (week 0)
- ustekinumab; 4 months prior to visit 1 (week 0)
- experimental products: 4 weeks or 5 half-lives (whichever is longer) prior to visit 1 (week 0)
Patients who have received topical treatment in the last 15 days.
Patients who have received treatment with phototherapy during the following periods:
- PUVA: 4 weeks before visit 1 (week 0)
- UV-B: 2 weeks before visit 1 (week 0)
History of concomitant serious systemic inflammatory cutaneous diseases.
Pregnant or lactating women
Patients who have participated in another clinical study in the 30 days prior to randomization.

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials

Study to evaluate the impact of early treatment with a budesonide / formoterol versus standard of care on the evolution of the disease in vulnerable patients with COVID-19: INHALAVID Trial

Phase 1

Fundació Eurecat

Updated 5/10/2021

Immunogenicity and safety of Rabies Vaccine, adimistered with two different simulated post exposure regimens

CompletedPhase 4

ovartis Healthcare Pvt Ltd

Updated 11/24/2021

A phase IV, open-label, randomized, multicenter trial assessing a reyataz-based substitution approach in the management of lipodystrophy syndrome.

BRISTOL-M.SQUIBB

Updated 5/1/2012

A phase IV, open-label, randomized, multicenter trial assessing the efficacy of a treatment maintenance phase with unboosted vs boosted Reyataz after an induction phase with Reytaz and Ritonavir in treatment naive HIV patients

BRISTOL-M.SQUIBB

Updated 4/24/2012

Phase IV, multicenter, open label, randomized study of Rebif® 44 mcg administered three times per week by subcutaneous injection compared with no treatment in the therapy of relapsing multiple sclerosis after mitoxantrone - Deescalation to Rebif® after Mitoxantrone therapy (REMAIN study)

Serono GmbH

Updated 1/7/2013

Efficacy of Bilastin in reduction of histaine-induce skin reactivity in healthy volunteers under fasted and fed conditions.

Phase 1

FAES FARMA, S.A.

Updated 9/17/2018

Phase IV, multicenter, randomized, open-label pilot study of Truvada or Emtricitabine alone versus HAART interruption in HIV-infected patients who need to interrupt HAART and who are infected with HIV isolates containing at least 2 TAMs (or K65R) and M184V (GMB Study).Estudio piloto, multicéntrico y aleatorizadode fase IV, de Truvada o emtricitabina solos frente a la suspensión del TARGA en pacientes infectados por el VIH-1 que deciden interrumpir el TARGA y que están infectados por cepas del VIH-1 que contienen como mínimo 2 TAM (o K65R) y M184V (estudio GMB) - GMB

Phase 1

Gilead Sciences, S.L.

Updated 4/19/2022

A phase IV, randomized, open-label, multi-center study in adults: Evaluation of long-term immunogenicity in subjects boosted with a new TBE vaccine for adults (free of protein-derived stabilizer) in study V48P2E1, 5 years after first booster immunization and Evaluation of booster kinetics in subjects boosted with a new TBE vaccine for adults (free of protein-derived stabilizer), 5 years after first booster immunization. - not available

Chiron Behring GmbH & Co KG

Updated 3/19/2012

Evaluation of GSK Biologicals’ Boostrix Polio in healthy adults, 10 years after a booster vaccination.

GlaxoSmithKline Biologicals

Updated 4/24/2012

Randomized study of three treatment arms; Colon mechanical preparation with oral and intravenous antibiotics versus oral and intravenous or only intravenous antibiotics. To confirm the decrease of infections in the surgical site with the first of the treatment arm after colon surgery.

Phase 1

Fundación Instituto de Investigación Sanitaria Aragón

Updated 2/1/2020

This study compares clinically and microscopically the response to two treatments, a steroid in cream and a foam that contains a steroid and a vitamin D analogue in patients with plaque psoriasis.

Recruitment & Eligibility

Study & Design

Related Trials

Study to evaluate the impact of early treatment with a budesonide / formoterol versus standard of care on the evolution of the disease in vulnerable patients with COVID-19: INHALAVID Trial

Immunogenicity and safety of Rabies Vaccine, adimistered with two different simulated post exposure regimens

A phase IV, open-label, randomized, multicenter trial assessing a reyataz-based substitution approach in the management of lipodystrophy syndrome.

A phase IV, open-label, randomized, multicenter trial assessing the efficacy of a treatment maintenance phase with unboosted vs boosted Reyataz after an induction phase with Reytaz and Ritonavir in treatment naive HIV patients

Phase IV, multicenter, open label, randomized study of Rebif® 44 mcg administered three times per week by subcutaneous injection compared with no treatment in the therapy of relapsing multiple sclerosis after mitoxantrone - Deescalation to Rebif® after Mitoxantrone therapy (REMAIN study)

Efficacy of Bilastin in reduction of histaine-induce skin reactivity in healthy volunteers under fasted and fed conditions.

Evaluation of GSK Biologicals’ Boostrix Polio in healthy adults, 10 years after a booster vaccination.

Randomized study of three treatment arms; Colon mechanical preparation with oral and intravenous antibiotics versus oral and intravenous or only intravenous antibiotics. To confirm the decrease of infections in the surgical site with the first of the treatment arm after colon surgery.

Clinical Trial Alerts

Clinical Trial Alerts